Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.64 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011237 | 1.00 | MME (0.64) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL31025643 | 1.00 | MME (0.64) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL30011197 | 1.00 | MME (0.64) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL31025645 | 1.00 | MME (0.64) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL30011266 | 1.00 | MME (0.64) | MMEACECPA1ACE2NPY1R | |
| SCHEMBL29761659 | 0.97 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL1987345 | 0.97 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29408691 | 0.97 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL1987346 | 0.97 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29938283 | 0.96 | MME (0.71) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | MME 776/4885ACE 836/4885CPA1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.